Evonik Industries (FRA:EVK) has been given a €24.00 ($27.91) target price by research analysts at Barclays in a research note issued on Monday, Borsen Zeitung reports. The brokerage presently has a “neutral” rating on the stock. Barclays‘s price target points to a potential upside of 1.10% from the stock’s current price.
A number of other research analysts have also commented on EVK. Goldman Sachs Group reaffirmed a “sell” rating on shares of Evonik Industries in a research report on Monday, October 14th. Warburg Research set a €36.00 ($41.86) price target on Evonik Industries and gave the company a “buy” rating in a research report on Thursday, August 1st. JPMorgan Chase & Co. set a €26.00 ($30.23) target price on Evonik Industries and gave the stock a “neutral” rating in a research report on Thursday, August 1st. Morgan Stanley set a €34.00 ($39.53) target price on Evonik Industries and gave the stock a “buy” rating in a research report on Monday, July 15th. Finally, Nord/LB set a €24.00 ($27.91) target price on Evonik Industries and gave the stock a “neutral” rating in a research report on Friday, October 4th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of €28.90 ($33.61).
EVK opened at €23.74 ($27.60) on Monday. The business has a 50 day simple moving average of €22.95 and a two-hundred day simple moving average of €24.47. Evonik Industries has a one year low of €26.78 ($31.14) and a one year high of €32.97 ($38.34).
About Evonik Industries
Evonik Industries AG engages in the specialty chemicals business worldwide. It operates through Nutrition & Care, Resource Efficiency, Performance Materials, and Services segments. The Nutrition & Care segment offers specialty chemicals, including amphoteric surfactants, ceramides, phytosphingosines, oleochemicals, quaternary derivatives, polyurethane additives, organically modified silicones, superabsorbents, amino acids and amino acid derivatives, synthesis products, pharmaceutical polymers, and DL-methionine for use in consumer goods, and animal nutrition and healthcare products.
Featured Story: Cost of Capital
Receive News & Ratings for Evonik Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evonik Industries and related companies with MarketBeat.com's FREE daily email newsletter.